MOLOGEN AG receives patent for cell based gene therapy

3. November 2008Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Berlin, November 3, 2008 - The Berlin biotech company MOLOGEN AG announced today that the Russian patent office is going to issue the patent for cell based gene therapy against cancer. MOLOGEN has developed an innovative product candidate for the treatment of cancers with the cell based gene therapy against cancer (MGN1601). In Europe, MOLOGEN is preparing an approval relevant clinical study of phase I/II with MGN1601, which should be carried out in the next year. MGN1601 has received Orphan Drug Status from the European Medicines Agency (EMEA). The Orphan Drug Status guarantees a ten year marketing exclusivity within the European Union. Furthermore, the company is being granted advisory support from the EMEA during the approval process. About cell based gene therapy Foreign cancer cells (allogenic tumour cells) are used in cell based gene therapy to activate the patient's immune system, so that it is enabled to recognise and fight the body's own tumour cells. To increase the efficiency of the immune system in this defence process the allogenic tumour cells are genetically modified before treatment with MIDGE® vectors. This modification leads to these allogenic tumour cells being especially well recognised by the patient's immune system. In addition dSLIM® immunomodulators are used which elicit a broad activation of the immune system. About MOLOGEN MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes in the research and development of innovative medicines based on DNA structures (DNA: deoxyribonucleic acid). Its patented DNA-based technology platforms MIDGE® and dSLIM® form a universal foundation with a wide range of possible applications. Activities focus on product developments for the treatment of cancer and vaccines for serious infections in humans and animals. MOLOGEN was founded in 1998 and was the first German biotechnology company to go public. MOLOGEN AG shares are listed in the General Standard of Deutsche Börse (ISIN DE 0006637200). Disclaimer concerning prognoses Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication. MOLOGEN AG Fabeckstr. 30, 14195 Berlin, Germany Contact: Joerg Petrass Email: investor@mologen.com Phone: +49-30-84 17 88-13 Fax: +49-30-84 17 88-50 --- End of Message --- MOLOGEN AG Fabeckstr. 30 Berlin Germany WKN: 663720; ISIN: DE0006637200; Listed: Freiverkehr in Börse Berlin, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, General Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;